WO1991005064A1 - A sensitive method for measurement of chimeric transcripts of dna containing translocations - Google Patents
A sensitive method for measurement of chimeric transcripts of dna containing translocations Download PDFInfo
- Publication number
- WO1991005064A1 WO1991005064A1 PCT/US1990/005427 US9005427W WO9105064A1 WO 1991005064 A1 WO1991005064 A1 WO 1991005064A1 US 9005427 W US9005427 W US 9005427W WO 9105064 A1 WO9105064 A1 WO 9105064A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrna
- measuring
- level
- translocation
- bcl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 230000005945 translocation Effects 0.000 title claims description 11
- 238000005259 measurement Methods 0.000 title abstract description 6
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 25
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 108700020796 Oncogene Proteins 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 206010001488 Aggression Diseases 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 3
- 230000003831 deregulation Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 3
- 230000016571 aggressive behavior Effects 0.000 claims description 2
- 208000012761 aggressive behavior Diseases 0.000 claims description 2
- 230000006399 behavior Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 abstract description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 15
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 201000003444 follicular lymphoma Diseases 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 244000241113 Plantago maritima Species 0.000 description 2
- 235000001991 Plantago maritima Nutrition 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- -1 dTTp Chemical compound 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- the present invention is related generally to the measurement of mRNA present in a biological sample. More particularly, the present invention is related to a sensitive and efficient method of measuring chimeric mRNA resulting from a chromosomal translocation, especially from biopsy specimens or the like, by a novel technique combining reverse transcription and polymerase chain reaction (PCR) .
- PCR polymerase chain reaction
- Follicular lymphoma is a common B-cell neoplasm which has remained largely an incurable disease. Approximately 95% of follicular lymphomas carry the t(14;18) (q32;q21) chromosomal translocation which results in joining of the putative oncogene bcl-2 on chromosome 18 to the immunoglobulin heavy chain joining region gene, JH, on chromosome 14 (Tsujimoto et al, 1984, Science 226:1097; Tsujimoto et al, 1985, Science 228:1440). This creates a unique segment of DNA composed of a joined bcl-2/JH sequence.
- an object of the present invention to provide a sensitive, reliable and efficient method for detecting micro quantities of mRNA found in biological samples, such as biopsy specimens. It is a further object of the present invention to provide a diagnostic test for detecting and predicting the course of conditions resulting from t(14;18) translocation, such as follicular lymphoma, Hodgkins disease and the like. Other obj cts and advantages will become evident from the following detailed description of the invention.
- Figure 1 shows different levels of expression of bcl-2.
- RNA extracted from tumor cells (lanes 1, 2, 3, 4) and from the cell line SUDHL-6 (lanes 5 and 6) was reverse transcribed and specifically amplified using the polymerase chain reaction technique. The amplified segments are subjected to electrophoresis and Southern blotting. Southern blots were then probed with a 32-P- labeled internal oligo.
- RNA extraction Two methods of RNA extraction are used, a microprocedure and a standard method.
- the microprocedure involves pelleting of an aliquot of 100,00 cells in sterile Eppendorf tubes, addition of about 11 ⁇ g of yeast RNA and suspension of cells and RNA in 100 ⁇ l of quanidine isothiocyanate buffer. This is layered over 100 ⁇ l of 5.7 M CsCl and centrifuged at 75,000 rpm for two hours in the Beckman TL-100. The resulting pellet is precipitated with ammonium acetate and ethanol and resuspended in 10 ⁇ l of sterile Tris EDTA buffer.
- the standard method uses the Fast Tract mRNA Isolation Kit (Invitrogen) and provides polyA selected mRNA.
- the extracted RNA is reverse transcribed using Moloney Murine Leukemia Virus Reverse Transcriptase (BRL) and one of two types of primers, " oligo dT12-18 and a mixture of a specific immunoglobulin heavy chain u constant region primer Cmu(GAGGGGGAAAAGGGTTGGGGCGGAT) and a specific immunoglobulin heavy chain gamma constant region primer C gamma (CAACTGTCTTGTCCACCTTGGTGTT) .
- the reverse transcription reaction is terminated after production of the first strand by addition of Na-EDTA, phenol chloroform extraction and ethanol precipitation.
- the cDNA is resuspended in 10-15 ⁇ l of tris EDTA buffer and 5 ⁇ l are amplified using the polymerase chain reaction technique (PCR) with Taq polymerase (Cetus) .
- PCR polymerase chain reaction technique
- the primers for PCR are the mu constant region and gamma constant region primers described above and the bcl-2 primer adjacent to the major breakpoint region (TTAGAGAGTTGCTTTACGTGGCCTG) reportedby Stetler-Stevenson et al (1988, Blood 72:1822) as well as 5' and 3' primers for a standard housekeeping gene such as beta actin.
- PCR is performed in the Thermocycler (Perkin Elmer Cetus) using a 100 mM Tris HC1 buffer, pH8.3, containing 500 mM KC1, 15 mM MgCl, 0.1% gelatin, 2.5 units of Taq polymerase, 200 ⁇ M each of dATP, dTTP, dCTP, and dGTP as well as 1 ⁇ g of each primer.
- the reaction mixture is heated to 91"C for 5 minutes, cooled to 55 ⁇ C for 5 minutes and brought to 74 ⁇ C for 5 minutes. Following this first round, samples are heated at 94 ⁇ C, 55°C, and 74°C for 1.5, 1.5, and 2 minutes, respectively, for a total of forty cycles.
- PCR sample Fifty percent of the PCR sample (25 ⁇ l) is resolved by electrophoresis (100V, 4-6 hr) in either 1.5% agarose (BRL) or 3% NuSieve (FMC) and 1% SeaKemp (FMC) agarose with 0.5 ⁇ g ethidium bromide/ml in Tris-Borate buffer. Alkaline Southern transfers are performed overnight using Genescreen Plus nylon filters (DuPont) and 0.4 N NaOH as a transfer buffer.
- BBL 1.5% agarose
- FMC NuSieve
- FMC SeaKemp
- Blots are then probed with a 32P-labeled 2.8 kb EcorRI/Hindlll fragment of the bcl-2 major breakpoint region, a 32P- labeled genomic JH SauIIIA fragment, and a 32P-labeled oligo with a sequence complimentary to a region immediately 3 » to the bcl-2 primer (CAACACAGACCCACCCAGAGCCCTCCTGCCCTCCTTCCGCGGGGGC) . Amplified segments ranging between 125 and 300 base pairs are detected by autoradiography.
- PCR amplification of contaminating genomic DNA produces a product several kilobases in length due to the nontranscribed region (intron) between JH and C mu or C gamma that is present in the rearranged gene, but not in the mRNA transcript.
- the technique of the present invention allows easy discrimination between PCR amplified products from the mRNA and genomic levels.
- the blots are also probed for the housekeeping gene amplified segment, such as beta actin. Comparison of the chimeric bcl-2/JH amplified segment intensity to the intensity of the beta actin amplified segment allows relative quantitation of the expression of bcl-2.
- RNA is extracted from tissue or mononuclear cells isolated from blood and subjected to the procedures described herein above. Presence of the translocation is indicative of tumor involvement in the setting of follicular lymphoma.
- This technique can be used to determine the level of bcl-2 expression and this may be utilized in deterr atioh of prognosis and thus in selection of proper treatment modalities.
- This technique can be used to measure the expression of any known oncogene in tumor tissue and thus be utilized as a prognostic indicator and for selection of appropriate therapy.
- This technique can be used to determine the presence of leukemic cells containing a translocation and thus allow early detection of relapse following therapy.
- This technique can be used to determine the level of expression of proteolytic enzymes involved in tumor invasion and metastasis and thus provide an indicator of metastatic potential in tumors.
- This technique is also useful in staging of Hodgkins disease in cases with known t(l4;18) translocation.
- mRNA is isolated, reverse transcribed and the cDNA fragment amplified and quantitated by standard methodologies well known in the art; a difference from the known steady state level of mRNA being indicative of the presence of t(14;18) translocation.
- the combined reverse transcription polymerase chain reaction is a novel technique for measurement of bcl-2 transcripts requiring only small quantities of RNA that can be easily obtained at the time of biopsy.
- bcl-2/JH mRNA Low levels (nanogram quantities) of bcl-2/JH mRNA can still be detected because following reverse transcription the specific bcl-2/JH segment is amplified up to a million fold by the polymerase chain reaction technique (Saiki et al, 1988, Sci. 239:487). Furthermore, amplified segments are run in agarose gels without formaldehyde thus removing a significant health hazard to laboratory personnel. Detection of a segment of genomic DNA or of RNA containing the t(14;18) translocation is diagnostic for tissue or peripheral blood involvement with follicular lymphoma in patients with this primary diagnosis and in addition, determination of levels of expression allows prediction of clinical cause.
- a diagnostic test for predicting the clinical course of a malignancy where aggressive behavior by malignant cells is associated with deregulation of an oncogene, lower expression of an antioncogene, or excessive production of proteolytic enzymes associated with metastasis comprises the step of measuring the level of target gene (oncogene, antioncogene or enzyme and the like) mRNA in tumor specimens by the method of the present invention and comparing the level of this mRNA with mRNA of normal uninvolved tissue, any statistically significant deviation from the normal levels being indicative of the clinical behavior of the tumor.
- target gene oncogene, antioncogene or enzyme and the like
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A novel method for measuring mRNA has been described. The method combines reverse transcriptase and polymerase chain reaction to achieve efficient and sensitive measurement.
Description
A SENSITIVE METHOD FOR MEASUREMENT OF CHIMERIC TRANSCRIPTS OF DNA CONTAINING TRANSLOCATIONS
The present invention is related generally to the measurement of mRNA present in a biological sample. More particularly, the present invention is related to a sensitive and efficient method of measuring chimeric mRNA resulting from a chromosomal translocation, especially from biopsy specimens or the like, by a novel technique combining reverse transcription and polymerase chain reaction (PCR) .
BACKGROUND OF THE INVENTION Follicular lymphoma is a common B-cell neoplasm which has remained largely an incurable disease. Approximately 95% of follicular lymphomas carry the t(14;18) (q32;q21) chromosomal translocation which results in joining of the putative oncogene bcl-2 on chromosome 18 to the immunoglobulin heavy chain joining region gene, JH, on chromosome 14 (Tsujimoto et al, 1984, Science 226:1097; Tsujimoto et al, 1985, Science 228:1440). This creates a unique segment of DNA composed of a joined bcl-2/JH sequence. Studies with cell lines have indicated that this translocation results in deregulation of bcl-2 expression, perhaps due to the effect of the IgH enhancer, leading to inappropriately high levels of the bcl-2 fusion transcript (Seto et al, 1988, E bo.J. 7:123; Hua, 1988, Oncoαene Res. 2:263). The high level expression of this chimeric transcript in follicular lymphoma has been proposed as a factor involved in the pathogenesis of follicular lymphoma (Tushjimoto, Y., 1989, Proc. Natl. Acad. Sci 86:1958) and the level of expression may be correlated with clinical course. However, the levels of the bcl-2-Ig fusion
transcript in follicular lymphoma. tissue has not been studied and correlated to clinical prognosis due to the relatively low levels of expression compared with other gene products and inherent difficulties in isolation of RNA containing sufficient quantities of the chimeric mRNA from biopsy specimens. Conventional methods involve preparation of large quantities of RNA, denaturation of RNA, electrophoresis in agarose formaldehyde gels and transfer to a nitrocellulose paper followed by hybridization with a specific probe and comparison to a product of known level of expression (Graninger et al, 1987, J. Clin. Invest. 80:1512). A reliable method for detecting micro quantities of mRNA found in biopsy samples is still needed. SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide a sensitive, reliable and efficient method for detecting micro quantities of mRNA found in biological samples, such as biopsy specimens. It is a further object of the present invention to provide a diagnostic test for detecting and predicting the course of conditions resulting from t(14;18) translocation, such as follicular lymphoma, Hodgkins disease and the like. Other obj cts and advantages will become evident from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
These and other objects, features and many of the attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein:
Figure 1 shows different levels of expression of bcl-2. RNA extracted from tumor cells (lanes 1, 2, 3, 4) and from the cell line SUDHL-6 (lanes 5 and 6) was reverse transcribed and specifically amplified using the polymerase chain reaction technique. The amplified segments are subjected to electrophoresis and Southern blotting. Southern blots were then probed with a 32-P- labeled internal oligo.
DETAILED DESCRIPTION OF THE INVENTION The above and various other objects and advantages of the invention are achieved by a method for detecting the presence of mRNA in a biological sample which comprises:
(a) extracting mRNA from a biological sample by any suitable procedure;
(b) then reverse transcribing the extracted mRNA using for example, moloney murine leukemia virus reverse transcriptase to obtain cDNA; and (c) then amplifying by PCR a diagnostic fragment of the cDNA and quantitating the product thus obtained by any suitable means known to one of ordinary skill in the art, such as radiometric, fluorometric, colorometric, densitometrie, photometric measurements and the like. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the
present invention, the preferred "methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference. Unless mentioned otherwise, the techniques employed or contemplated herein are standard methodologies well known to one of ordinary skill in the art. The materials, methods and examples are illustrative only and not limiting.
MATERIALS AND METHODS Materials. The following is a list of materials >.and their sources.
Guanidine isothiocyanate - Sigma; Cesium chloride - Bethesda Research Lab (BRL) ; Moloney urine leukemia virus reverse transcriptase - BRL; Fast tract mRNA isolation kit-Invitrogen; Tris and agarose - BRL; EDTA - Fisher; Taq polymerase - Cetus; dATP, dTTp, dCTP, dGTP - Pharmacia; Nusieve and Sea kemp agarose - FMC; Genescreen - DuPont; 32-P-gamma ATP - ICN. Methods
Two methods of RNA extraction are used, a microprocedure and a standard method. The microprocedure involves pelleting of an aliquot of 100,00 cells in sterile Eppendorf tubes, addition of about 11 μg of yeast RNA and suspension of cells and RNA in 100 μl of quanidine isothiocyanate buffer. This is layered over 100 μl of 5.7 M CsCl and centrifuged at 75,000 rpm for two hours in the Beckman TL-100. The resulting pellet is precipitated with ammonium acetate and ethanol and resuspended in 10 μl of sterile Tris EDTA buffer.
The standard method uses the Fast Tract mRNA Isolation Kit (Invitrogen) and provides polyA selected mRNA. The extracted RNA is reverse transcribed using Moloney Murine Leukemia Virus Reverse Transcriptase (BRL)
and one of two types of primers," oligo dT12-18 and a mixture of a specific immunoglobulin heavy chain u constant region primer Cmu(GAGGGGGAAAAGGGTTGGGGCGGAT) and a specific immunoglobulin heavy chain gamma constant region primer C gamma (CAACTGTCTTGTCCACCTTGGTGTT) . The reverse transcription reaction is terminated after production of the first strand by addition of Na-EDTA, phenol chloroform extraction and ethanol precipitation. The cDNA is resuspended in 10-15 μl of tris EDTA buffer and 5 μl are amplified using the polymerase chain reaction technique (PCR) with Taq polymerase (Cetus) . The primers for PCR are the mu constant region and gamma constant region primers described above and the bcl-2 primer adjacent to the major breakpoint region (TTAGAGAGTTGCTTTACGTGGCCTG) reportedby Stetler-Stevenson et al (1988, Blood 72:1822) as well as 5' and 3' primers for a standard housekeeping gene such as beta actin.
PCR is performed in the Thermocycler (Perkin Elmer Cetus) using a 100 mM Tris HC1 buffer, pH8.3, containing 500 mM KC1, 15 mM MgCl, 0.1% gelatin, 2.5 units of Taq polymerase, 200 μM each of dATP, dTTP, dCTP, and dGTP as well as 1 μg of each primer. The reaction mixture is heated to 91"C for 5 minutes, cooled to 55βC for 5 minutes and brought to 74βC for 5 minutes. Following this first round, samples are heated at 94βC, 55°C, and 74°C for 1.5, 1.5, and 2 minutes, respectively, for a total of forty cycles. Fifty percent of the PCR sample (25μl) is resolved by electrophoresis (100V, 4-6 hr) in either 1.5% agarose (BRL) or 3% NuSieve (FMC) and 1% SeaKemp (FMC) agarose with 0.5 μg ethidium bromide/ml in Tris-Borate buffer. Alkaline Southern transfers are performed overnight using Genescreen Plus nylon filters
(DuPont) and 0.4 N NaOH as a transfer buffer. Blots are then probed with a 32P-labeled 2.8 kb EcorRI/Hindlll fragment of the bcl-2 major breakpoint region, a 32P- labeled genomic JH SauIIIA fragment, and a 32P-labeled oligo with a sequence complimentary to a region immediately 3 » to the bcl-2 primer (CAACACAGACCCACCCAGAGCCCTCCTGCCCTCCTTCCGCGGGGGC) . Amplified segments ranging between 125 and 300 base pairs are detected by autoradiography. PCR amplification of contaminating genomic DNA produces a product several kilobases in length due to the nontranscribed region (intron) between JH and C mu or C gamma that is present in the rearranged gene, but not in the mRNA transcript. Thus, the technique of the present invention allows easy discrimination between PCR amplified products from the mRNA and genomic levels. The blots are also probed for the housekeeping gene amplified segment, such as beta actin. Comparison of the chimeric bcl-2/JH amplified segment intensity to the intensity of the beta actin amplified segment allows relative quantitation of the expression of bcl-2. Utilities:
1. This technique can be used to diagnose tissue or peripheral blood involvement with lymphoma. RNA is extracted from tissue or mononuclear cells isolated from blood and subjected to the procedures described herein above. Presence of the translocation is indicative of tumor involvement in the setting of follicular lymphoma.
2. This technique can be used to determine the level of bcl-2 expression and this may be
utilized in deterr atioh of prognosis and thus in selection of proper treatment modalities.
3. This technique can be used to measure the expression of any known oncogene in tumor tissue and thus be utilized as a prognostic indicator and for selection of appropriate therapy.
4. This technique can be used to determine the presence of leukemic cells containing a translocation and thus allow early detection of relapse following therapy.
5. This technique can be used to determine the level of expression of proteolytic enzymes involved in tumor invasion and metastasis and thus provide an indicator of metastatic potential in tumors.
6. This technique is also useful in staging of Hodgkins disease in cases with known t(l4;18) translocation. As mentioned herein before, mRNA is isolated, reverse transcribed and the cDNA fragment amplified and quantitated by standard methodologies well known in the art; a difference from the known steady state level of mRNA being indicative of the presence of t(14;18) translocation. In summary, the combined reverse transcription polymerase chain reaction is a novel technique for measurement of bcl-2 transcripts requiring only small quantities of RNA that can be easily obtained at the time of biopsy. Low levels (nanogram quantities) of bcl-2/JH mRNA can still be detected because following reverse transcription the specific bcl-2/JH segment is amplified up to a million fold by the polymerase chain reaction
technique (Saiki et al, 1988, Sci. 239:487). Furthermore, amplified segments are run in agarose gels without formaldehyde thus removing a significant health hazard to laboratory personnel. Detection of a segment of genomic DNA or of RNA containing the t(14;18) translocation is diagnostic for tissue or peripheral blood involvement with follicular lymphoma in patients with this primary diagnosis and in addition, determination of levels of expression allows prediction of clinical cause. Therapy modified according to the prognosis indicated by this determination may achieve better patient survival. The t(14;18) translocation has recently been found in Hodgkins disease and, therefore, the combined reverse transcription polymerase chain reaction measurement of bcl-2/JH transcripts can be applied to this disease as well.
The method could also be applied to measure the expression of oncogenes and enzyme markers involved in tumor invasion and metastasis in other neoplasms. Furthermore, this diagnostic test allows a more accurate assessment of the aggressiveness of individual tumors and appropriate adjustment of therapy. A diagnostic test for predicting the clinical course of a malignancy where aggressive behavior by malignant cells is associated with deregulation of an oncogene, lower expression of an antioncogene, or excessive production of proteolytic enzymes associated with metastasis, comprises the step of measuring the level of target gene (oncogene, antioncogene or enzyme and the like) mRNA in tumor specimens by the method of the present invention and comparing the level of this mRNA with mRNA of normal uninvolved tissue, any statistically significant
deviation from the normal levels being indicative of the clinical behavior of the tumor.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of t is application and scope of the appended claims.
Claims
1. A method for measuring mRNA in a biological sample, comprising the steps of:
(a) isolating mRNA from a biological sample; (b) reverse transcribing the isolated mRNA from step (a) to obtain cDNA; (c) amplifying the cDNA obtained from step (b) by polymerase chain reaction and measuring the product thus obtained by any suitable quantitating means.
2. A diagnostic test for predicting the clinical course of a malignancy where aggressive behavior by malignant cells is associated with deregulation of an oncogene, lower expression of an antioncogene, or excessive production of proteolytic enzymes associated with metastasis, comprising the steps of measuring the level of target gene mRNA in tumor specimen by the method of claim 1 and comparing the level of said mRNA with mRNA of normal uninvolved tissue, a deviation from the normal level being indicative of the clinical behavior of the tumor.
3. A diagnostic test for determining the presence of a disease caused by translocation, comprising the step of measuring the chimeric mRNA produced by the DNA segment containing the translocation, by the method of claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41611789A | 1989-10-02 | 1989-10-02 | |
| US416,117 | 1989-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991005064A1 true WO1991005064A1 (en) | 1991-04-18 |
Family
ID=23648611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1990/005427 WO1991005064A1 (en) | 1989-10-02 | 1990-09-27 | A sensitive method for measurement of chimeric transcripts of dna containing translocations |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0494968A4 (en) |
| AU (1) | AU630001B2 (en) |
| CA (1) | CA2067114A1 (en) |
| WO (1) | WO1991005064A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006248A1 (en) * | 1991-09-16 | 1993-04-01 | The United States Of America Represented By The Secretary, Department Of Health & Human Services | Detection method for c-raf-1 genes |
| GB2260811A (en) * | 1991-10-23 | 1993-04-28 | Yorkshire Cancer Research Camp | Diagnosis of malignant tumours by mRNA detection |
| WO1993024655A1 (en) * | 1992-05-27 | 1993-12-09 | Amersham International Plc | Rna analysis |
| EP0597699A2 (en) * | 1992-11-10 | 1994-05-18 | Tosoh Corporation | Protein secreted by cancer cells |
| DE4431174A1 (en) * | 1994-09-01 | 1996-03-07 | Deutsches Krebsforsch | Detecting tumour specific mRNA by conversion to cDNA and amplification |
| EP0731806A1 (en) * | 1993-12-03 | 1996-09-18 | St. Jude Children's Research Hospital | SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF |
| US5643730A (en) * | 1991-09-23 | 1997-07-01 | Pfizer Inc. | Process for detecting specific mRNA and DNA in cells |
| US5869308A (en) * | 1988-08-26 | 1999-02-09 | The United States Of America As Represented By The Department Of The Health And Human Services | Detection method for C-RAF-1 genes |
| US6696548B2 (en) | 1993-12-03 | 2004-02-24 | St. Jude Children's Research Hospital | Antibodies for recognition of alk protein tyrosine/kinase receptor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358586A (en) * | 1980-12-23 | 1982-11-09 | Harvey Rubin | Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide |
| US4483920A (en) * | 1982-05-17 | 1984-11-20 | Hahnemann University | Immobilization of message RNA directly from cells onto filter material |
| US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009456A1 (en) * | 1989-02-16 | 1990-08-23 | Viktor Balazs | Malignancy test (cancer test) using the polymerase chain reaction |
-
1990
- 1990-09-27 WO PCT/US1990/005427 patent/WO1991005064A1/en not_active Application Discontinuation
- 1990-09-27 CA CA 2067114 patent/CA2067114A1/en not_active Abandoned
- 1990-09-27 AU AU66061/90A patent/AU630001B2/en not_active Ceased
- 1990-09-27 EP EP19900915643 patent/EP0494968A4/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358586A (en) * | 1980-12-23 | 1982-11-09 | Harvey Rubin | Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide |
| US4483920A (en) * | 1982-05-17 | 1984-11-20 | Hahnemann University | Immobilization of message RNA directly from cells onto filter material |
| US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP0494968A4 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869308A (en) * | 1988-08-26 | 1999-02-09 | The United States Of America As Represented By The Department Of The Health And Human Services | Detection method for C-RAF-1 genes |
| WO1993006248A1 (en) * | 1991-09-16 | 1993-04-01 | The United States Of America Represented By The Secretary, Department Of Health & Human Services | Detection method for c-raf-1 genes |
| US5643730A (en) * | 1991-09-23 | 1997-07-01 | Pfizer Inc. | Process for detecting specific mRNA and DNA in cells |
| GB2260811A (en) * | 1991-10-23 | 1993-04-28 | Yorkshire Cancer Research Camp | Diagnosis of malignant tumours by mRNA detection |
| GB2260811B (en) * | 1991-10-23 | 1995-07-05 | Yorkshire Cancer Research Camp | Detection of malignant tumours |
| WO1993024655A1 (en) * | 1992-05-27 | 1993-12-09 | Amersham International Plc | Rna analysis |
| US5665544A (en) * | 1992-05-27 | 1997-09-09 | Amersham International Plc | RNA fingerprinting to determine RNA population differences |
| EP0597699A2 (en) * | 1992-11-10 | 1994-05-18 | Tosoh Corporation | Protein secreted by cancer cells |
| EP0597699A3 (en) * | 1992-11-10 | 1994-09-28 | Tosoh Corp | Protein secreted by cancer cells. |
| EP0731806A1 (en) * | 1993-12-03 | 1996-09-18 | St. Jude Children's Research Hospital | SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF |
| EP0731806A4 (en) * | 1993-12-03 | 1998-12-16 | St Jude Childrens Res Hospital | SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF |
| US6174674B1 (en) | 1993-12-03 | 2001-01-16 | St. Jude Children's Research Hospital | Method of detecting a chromosomal rearrangement involving a breakpoint in the ALK or NPM gene |
| US6451997B1 (en) | 1993-12-03 | 2002-09-17 | St. Jude Children's Research Hospital | Kits for detecting chromosomal rearrangements |
| US6696548B2 (en) | 1993-12-03 | 2004-02-24 | St. Jude Children's Research Hospital | Antibodies for recognition of alk protein tyrosine/kinase receptor |
| DE4431174A1 (en) * | 1994-09-01 | 1996-03-07 | Deutsches Krebsforsch | Detecting tumour specific mRNA by conversion to cDNA and amplification |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0494968A1 (en) | 1992-07-22 |
| EP0494968A4 (en) | 1992-11-25 |
| AU630001B2 (en) | 1992-10-15 |
| AU6606190A (en) | 1991-04-28 |
| CA2067114A1 (en) | 1991-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE49542E1 (en) | Method for the detection of cancer | |
| Branford et al. | Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics | |
| US20100279877A1 (en) | Method for Detection of Melanoma | |
| US5942390A (en) | Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism | |
| CN105316341B (en) | A kind of LncRNA and its application in marker or prostate cancer prognosis recurrence marker is detected as prostate cancer | |
| EP1080227B1 (en) | Method of diagnosing, monitoring, and staging colon cancer | |
| AU698604B2 (en) | Methods of screening for Crohn's disease using TNF microsatellite alleles | |
| Olsson et al. | Real-time t (11; 14) and t (14; 18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD) | |
| CA3026809A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| AU630001B2 (en) | A sensitive method for measurement of chimeric transcripts of dna containing translocations | |
| WO1999004037A1 (en) | Detection of k-ras mutations in cancer | |
| WO1998046798A1 (en) | Enhanced reverse transcriptase polymerase chain assay to detect mn in patients with renal cell carcinoma | |
| WO1998046798A9 (en) | Enhanced reverse transcriptase polymerase chain assay to detect mn in patients with renal cell carcinoma | |
| US6153388A (en) | Method of determining melanoma micrometastasis using tyrosinase | |
| US6287775B1 (en) | Early detection of ovarian carcinoma using p16 gene products | |
| EP1082460A1 (en) | A novel method of diagnosing, monitoring, and staging prostate cancer | |
| IL131167A (en) | Apc mutuation associated with familial colorectal cancer in ashkenazi jews | |
| US20040253622A1 (en) | Androgen regulated prostate specific polypeptide-5 (ARP-5) | |
| JP2008099664A (en) | Detection of lymph node metastasis from gastric carcinoma | |
| WO2001053535A2 (en) | Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation | |
| US6949339B1 (en) | Method of diagnosing, monitoring, and staging colon cancer | |
| KR100868883B1 (en) | Detection of Neuroblastoma Cells | |
| US20100167278A1 (en) | Novel Method of Diagnosing, Monitoring, and Staging Prostate Cancer | |
| KR102131519B1 (en) | Biomarker for diagnosing of liver cancer metastasis or predicting prognosis of the same and use thereof | |
| JP4870976B2 (en) | Test method for autoimmune disease using whole blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2067114 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1990915643 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1990915643 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1990915643 Country of ref document: EP |